Amicus at Jefferies Conference: Strategic Growth and Profitability

Amicus Therapeutics (FOLD) presented at the Jefferies Global Healthcare Conference 2025, reaffirming its path to GAAP profitability in the second half of 2025, driven by Galafold's mid-teen patient growth and Pombility's projected 50-65% revenue increase this year to $105-115 million. The company highlighted Galafold's growth potential through improved diagnostics and IP protection extending to 2037, while also emphasizing the strategic acquisition of the Dimerix asset for FSGS, a potential US blockbuster, for $30 million upfront with $75 million in developmental milestones.

Analysis

Amicus Therapeutics (NASDAQ:FOLD) is progressing towards GAAP profitability, anticipated in the second half of 2025, supported by strong performance from its key drug Galafold and the expanding market presence of Pombility. Galafold achieved mid-teen patient growth, with a 14% increase in Q1, and a full-year revenue growth forecast of 10-15%, buoyed by enhanced diagnostic initiatives, including AI collaborations to tap into the significant undiagnosed Fabry patient population, and intellectual property protection extended to 2037 via a settlement with Teva. Pombility is projected to generate $105-115 million in revenue this year, a 50-65% increase, driven by patient uptake in key markets, although switching dynamics from competing treatments like Sanofi's Nexviazyme are being closely monitored, with significant shifts expected after patients complete two years on the alternative. Strategically, Amicus has acquired rights to a Dimerix asset for Focal Segmental Glomerulosclerosis (FSGS) for $30 million upfront plus $75 million in developmental milestones, viewing it as a potential US blockbuster currently in Phase 3. Having achieved non-GAAP profitability in 2024, the company is also pursuing further business development for late-stage or commercial rare disease assets, aiming to leverage existing infrastructure. Management highlighted that Galafold's sustained growth, driven by new diagnoses and market penetration, and its extended exclusivity, may not be fully reflected in current investor valuations, a sentiment underscored by the strongly positive market sentiment signals.

Key Decisions for Investors

• Investors should monitor Amicus's progress towards its stated goal of GAAP profitability in the second half of 2025, which hinges on continued strong revenue growth from Galafold (10-15% forecast) and Pombility ($105-115 million projected revenue).
• Consider the long-term growth runway and profitability of Galafold, supported by intellectual property protection until 2037, ongoing efforts to diagnose the substantial undiagnosed Fabry patient population, and its high contribution margin once established.
• Closely watch for Pombility's ability to capture market share, particularly regarding patient switching from Nexviazyme after the two-year mark, and upcoming Phase 3 data for the acquired Dimerix FSGS asset, which represents a significant pipeline opportunity.
• Evaluate the company's disciplined approach to business development and capital allocation, ensuring that acquisitions like the Dimerix asset and potential future deals align with leveraging existing infrastructure and support sustainable profitability.